Opens in a new tab

Membranous Nephropathy: FDA Approves the First Drug, Gazyva

Table of Content

Primary membranous nephropathy: a nephrologist reviews urine protein and kidney blood test results with a patient

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

For the first time, there is an FDA-approved drug made specifically for primary membranous nephropathy, an autoimmune kidney disease and one of the most common causes of nephrotic syndrome in adults. In mid-November 2026, the US Food and Drug Administration approved obinutuzumab (Gazyva, Genentech/Roche) for adults with primary membranous nephropathy who are at risk of disease progression, to induce remission of proteinuria, the leak of protein into the urine. The approval applies in the United States; Roche has also submitted the application to other regulators, including the EMA.

For patients, the most practical part of this story is that membranous nephropathy is monitored almost entirely through lab tests: urine protein, blood albumin, kidney function, and a disease-specific antibody called anti-PLA2R. If you need the basics first, read our guide to protein in urine: causes, symptoms and risks.

What the FDA approved, and why it matters

Until now, doctors have treated membranous nephropathy with drugs borrowed from other conditions, such as rituximab, calcineurin inhibitors like tacrolimus, or cyclophosphamide with steroids, all used off-label. The approval is based on the phase 3 MAJESTY trial, published in the New England Journal of Medicine. It enrolled 142 adults with primary membranous nephropathy, who received either intravenous obinutuzumab or oral tacrolimus.

  • Complete remission at two years (urine protein-to-creatinine ratio of 0.3 g/g or lower, about 30 mg/mmol, with stable kidney function): about 37% with obinutuzumab versus 6% with tacrolimus.
  • Complete or partial remission at two years: 50% versus about 13%, according to Roche.
  • No significant difference in sustained loss of kidney function, an outcome that needs longer follow-up.
  • Most common side effects: infusion reactions and upper respiratory tract infections; the investigators reported no new safety signals.

Obinutuzumab is a monoclonal antibody that depletes B cells, the immune cells that produce the autoantibodies driving the disease. It was already approved for certain blood cancers, lupus nephritis and childhood idiopathic nephrotic syndrome. One caveat noted by nephrologists: MAJESTY compared it with tacrolimus, not with rituximab, so we do not yet know whether it outperforms the drug most kidney specialists use first.

Membranous nephropathy in brief

In membranous nephropathy, the immune system makes antibodies against a protein on podocytes, the cells that stop protein passing from the blood into the urine. Antibody deposits damage this filter. Protein spills into the urine, blood albumin falls, and swelling (oedema) develops, often in the ankles, legs or around the eyes. Roche cites an incidence of about 1.2 new cases per 100,000 people per year in the US.

The course varies widely. Roughly a third of patients go into remission on their own, a third keep some degree of proteinuria, and a third progress towards severe kidney failure. Blood clots and infections are the main short-term complications. The disease can also be secondary to another condition, such as lupus, hepatitis B, certain medicines or cancer, so doctors always look for a cause.

Which tests can monitor or screen for this?

The first clue is often a urine dipstick positive for protein or persistently frothy urine (see foamy urine explained). These are the key tests:

TestWhat it measuresWhy it matters
Urine protein-to-creatinine ratio (UPCR)How much protein you lose in your urineAbove about 3 g/g (about 300 mg/mmol) suggests nephrotic-range proteinuria; 0.3 g/g (about 30 mg/mmol) or lower defined complete remission in MAJESTY
Serum albuminThe main blood protein, which falls when protein leaks outBelow 30 g/L (3.0 g/dL) with heavy proteinuria defines nephrotic syndrome; very low levels raise the risk of clots
Anti-PLA2R antibody (blood)The autoantibody found in about 70% to 80% of primary casesA positive result can support the diagnosis without a biopsy in some patients; falling levels signal a response
Creatinine and eGFRHow well the kidneys filterA rapid decline is a red flag that changes treatment
Lipid profile and electrolytesEffects of nephrotic syndrome on the bodyCholesterol often rises sharply and is checked at follow-up appointments

The anti-PLA2R test has transformed care. Antibody levels usually fall weeks to months before urine protein does, so they give an earlier indication of whether a treatment is working. For more on kidney markers, see our guides to the albumin-to-creatinine ratio, low albumin and the kidney function panel.

What this means for you

Not everyone with membranous nephropathy needs immunosuppressive treatment. People at low risk may first receive supportive care, such as blood pressure medicines that lower proteinuria and a low-salt diet, because spontaneous remission is common. The new approval matters most for people at higher risk of progression. It may also give doctors a licensed option for patients who do not respond to rituximab, which a 2026 meta-analysis puts at 35% to 45% of patients.

In the United States, an FDA label can also make insurance coverage easier, a point raised by nephrologists interviewed after the decision. Your nephrologist will weigh up your urine protein, albumin, kidney function and antibody level before choosing a treatment.

Recent scientific advances

Several 2026 studies add context to MAJESTY. A meta-analysis pooling smaller studies found remissions with obinutuzumab in patients who had never been treated, in those previously treated, and even in people whose disease resisted rituximab, with albumin rising and proteinuria falling over time. Those groups cannot be compared head to head, though.

A November 2026 expert review suggests the best candidates are people with high anti-PLA2R levels, high-risk disease, or rituximab failure or intolerance. A retrospective study found that the anti-PLA2R level measured at six months predicted remission better than proteinuria alone. Put simply, a blood test is becoming a steering wheel for treatment decisions, not just a diagnostic tool.

When to see a doctor

  • If a urine test shows protein, or your urine stays frothy day after day.
  • If your ankles, legs or eyelids swell, or you put on weight quickly without explanation.
  • If you have membranous nephropathy and your albumin falls, your creatinine rises, or your anti-PLA2R level climbs again.
  • Call 999 for sudden breathlessness, chest pain, or a painful, swollen calf, which can signal a blood clot.

Glossary

  • Membranous nephropathy: an autoimmune disease in which antibodies are deposited on the kidney filter; "primary" means no other cause is found.
  • Nephrotic syndrome: heavy protein loss in the urine with low blood albumin, often with swelling and high cholesterol.
  • Anti-PLA2R: an autoantibody against the phospholipase A2 receptor on podocytes, found in most primary cases.
  • Podocyte: a kidney cell that keeps protein out of the urine.
  • B cell: a white blood cell that produces antibodies.
  • Complete remission: urine protein back to a near-normal level with stable kidney function.

FAQ

Is Gazyva the first treatment for membranous nephropathy?

It is the first drug approved by the FDA specifically for adults with primary membranous nephropathy. Other medicines, such as rituximab, have been used off-label for years and remain standard options.

Can a blood test diagnose membranous nephropathy?

In someone with nephrotic syndrome and normal kidney function, a positive anti-PLA2R test can strongly support the diagnosis, and some patients can avoid a kidney biopsy. A negative test does not rule the disease out, and a biopsy is then usually needed.

What does a high anti-PLA2R level mean?

Higher levels are linked to more active disease and a higher risk of progression. A falling level during treatment is a good sign and usually comes before urine protein improves.

Can membranous nephropathy go away on its own?

Yes. Roughly a third of people with primary membranous nephropathy go into spontaneous remission, which is why doctors assess the risk before starting immunosuppressive drugs.

Which tests are repeated during follow-up?

Typically the urine protein-to-creatinine ratio, serum albumin, creatinine and eGFR, electrolytes, lipids, and the anti-PLA2R level when the antibody was positive at diagnosis.

Sources

Other articles

Understand your own blood test results with AI DiagMe

Urine protein, albumin, creatinine, eGFR: if you have your kidney results to hand, AI DiagMe explains each value in plain language, compares it with reference ranges, and helps you prepare the right questions for your nephrologist.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practising hospital physicians in specialties such as haematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr Claude Tchonko is a haematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specialises in the management of haematological malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimisation of care pathways in onco-haematology.

    Author of a reference work, ‘Lymphoid Haematological Malignancies in Mali’, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Haematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Haematology and an inter-university diploma (DIU) in Onco-Haematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming soon